A practical guide for biomedical researchers, clinicians, biostatisticians, and graduate students in biostatistics, this volume covers the latest developments in the analysis and modeling of interval-censored time-to-event data. Top researchers from academia, biopharmaceutical industries, and government agencies show how up-to-date statistical m

�ber die Autorin bzw. den Autor

Ding-Geng (Din) Chen, Ph.D., is a professor at the University of Rochester Medical Center. Dr. Chen is also a senior biostatistics consultant for biopharmaceutical companies and government agencies. He is a member of the ASA, chair-elect for the STAT section of the American Public Health Association, and an associate editor of the Journal of Statistical Computation and Simulation. He has authored/co-authored more than 80 journal publications on biostatistical methodologies and applications and co-authored two books with Dr. Peace, Clinical Trial Methodology and Clinical Trial Data Analysis Using R.

Jianguo (Tony) Sun, Ph.D., is a professor of statistics at the University of Missouri. He has worked on failure time analysis for over 20 years and published many papers on failure time analysis, chemometrics, longitudinal data analysis, and panel count data analysis. He also authored the book, Statistical Analysis of Interval-censored Failure Time Data.

Karl E. Peace, Ph.D., is the Georgia Cancer Coalition Distinguished Cancer Scholar, senior research scientist, and professor of biostatistics in the Jiann-Ping Hsu College of Public Health at Georgia Southern University, where he is the founding director of the Center for Biostatistics. A fellow of the ASA, he has received numerous honors, including citations from the Georgia and U.S. Congressional Houses for contributions to education and public health, the Hall of Fame Alumni Award from Georgia Southern University System’s Board of Regents, and the ASA Award for Statistical Contributions for the Betterment of Society. Dr. Peace has authored/edited ten books and authored/co-authored over 200 articles. His primary research interests include drug research and development, clinical trial methodology, time-to-event methodology, and public health applications of biostatistics.

��ber diesen Titel� kann sich auf eine andere Ausgabe dieses Titels beziehen.